💊 Rapamycin Immunosuppression Side Effect Balance Simulator

mTOR Signaling in Immune Cell Function

Placeholder: mTOR complexes shape T-cell metabolism and differentiation.

• mTORC1/2: Pathway (Placeholder short note)
• T-cells: Key cells (Placeholder short note)
• mTOR inhibitor: Drug class (Placeholder short note)
• 1970s: Discovery era (Placeholder short note)

How mTOR shapes immune cell activation

Placeholder: mTOR integrates nutrient and growth signals for immune cells.

Infection Risk at Higher Rapamycin Doses

Placeholder: transplant-level dosing raises susceptibility to infection.

• Dose intensity: Risk driver (Placeholder short note)
• Opportunistic infection: Common issue (Placeholder short note)
• Transplant rejection: Typical use (Placeholder short note)
• Benefit vs risk: Trade-off (Placeholder short note)

Why higher doses raise infection susceptibility

Placeholder: stronger immune suppression reduces pathogen clearance ability.

Low-Dose Longevity vs Transplant-Dose Immunosuppression

Placeholder: dose context determines whether effects favor longevity or rejection control.

• Healthspan: Low-dose goal (Placeholder short note)
• Graft survival: High-dose goal (Placeholder short note)
• Minimal: Low-dose risk (Placeholder short note)
• Substantial: High-dose risk (Placeholder short note)

Comparing longevity and transplant dosing regimens

Placeholder: dosing strategy shifts the balance of benefit and suppression.

Monitoring for Infection Signs During Therapy

Placeholder: routine checks help detect infection before it worsens.

• Blood counts: Monitor (Placeholder short note)
• Fever screening: Monitor (Placeholder short note)
• Regular visits: Frequency (Placeholder short note)
• Early detection: Goal (Placeholder short note)

What clinical monitoring looks for

Placeholder: monitoring tracks infection markers and immune status regularly.

Adjusting Dose for Risk-Benefit Balance

Placeholder: dose titration aims to preserve benefit while limiting risk.

• Titration: Approach (Placeholder short note)
• Risk signs: Trigger (Placeholder short note)
• Balanced regimen: Outcome (Placeholder short note)
• Clinician: Decision-maker (Placeholder short note)

How dose is adjusted for individual risk

Placeholder: adjustments weigh individual infection risk against therapy goals.

Placeholder: individualized dosing balances immunosuppressive benefit and infection risk.